Gordon Op-Ed: Connecticut Should Stand Behind Its Approach to Hemp Regulation

Originally published by the Hartford Courant on August 19, 2026, this commentary by AACPN Director of Healthcare Policy & External Affairs John R. Gordon examines Connecticut’s approach to regulating hemp-derived consumer products amid an evolving national policy debate. It considers how proposed federal restrictions could affect Connecticut’s existing regulatory framework, consumers who rely on these products, and the state’s ability to continue balancing responsible regulation, consumer protection, and access.

Connecticut has become a national leader in approaching emerging healthcare issues through research, responsible regulation, and evidence-based policymaking. That philosophy is reflected not only in Connecticut’s regulation of consumable hemp products, but also in its willingness to advance research into emerging therapies before adopting public policy that could outpace the scientific evidence.

That is why it is surprising that Connecticut Attorney General William Tong is leading a coalition of 35 attorneys general in urging Congress not to delay upcoming federal restrictions on consumable hemp products, set to take effect on November 12.

Tong’s office correctly notes that protecting children, preventing youth access, addressing synthetic cannabinoids, and ensuring product safety are legitimate public policy objectives deserving serious attention. Where Tong’s coalition falls short is its assumption that delaying the November federal changes would inevitably return the country to an unregulated marketplace.

Congress is presently considering legislative approaches that would strengthen federal oversight of consumable hemp products through enhanced manufacturing standards, product testing, labeling requirements, age restrictions, and other safeguards while preserving the regulatory authority states have already exercised. Those proposals seek to strengthen national standards without displacing existing state regulatory systems.

The debate also has important healthcare implications. Veterans, first responders, trauma survivors, social workers, healthcare professionals, caregivers, and others in Connecticut whose physical and/or mental health has been adversely impacted in the service of others have increasingly incorporated regulated hemp-derived products into broader wellness or symptom-management strategies. The upcoming federal restrictions on consumable hemp products, as supported by Tong and the coalition he leads, would adversely affect many of those individuals by disrupting access to Connecticut’s regulated consumable hemp marketplace.

Connecticut has already established licensing requirements, testing standards, packaging and labeling requirements, age restrictions, and controlled retail channels designed to protect consumers while allowing lawful access to regulated products. This reflects Connecticut’s deliberate policy decision to regulate rather than prohibit consumable hemp products.

The coalition’s letter warns that delaying the November federal changes would allow “the return of unregulated intoxicating cannabis products.” The letter further argues that delaying implementation “will almost guarantee that these state efforts at regulation will be thrown into chaos.”

Neither conclusion follows for Connecticut. A temporary congressional delay would preserve—not dismantle—the regulatory framework the state has spent years building while lawmakers complete their work on stronger national standards.

It is the federal restriction scheduled to take effect on November 12, not a temporary delay followed by a comprehensive federal regulatory framework, that would fundamentally alter Connecticut’s existing, regulated consumable hemp marketplace.

Connecticut’s experience demonstrates that states are fully capable of establishing robust consumer protections while Congress considers whether national standards should supplement those existing systems. Strong federal oversight and strong state oversight are complementary, not contradictory. The question is not whether consumable hemp products should be regulated, but how federal and state regulation can work together most effectively.

No one disputes that stronger safeguards are needed. The real question is whether Congress should build upon the successful regulatory systems states like Connecticut have already developed or replace them with a federal approach that renders years of state policy-making largely irrelevant.

For veterans, first responders, healthcare professionals, trauma survivors, social workers, caregivers, and those who have been adversely impacted in the service of others, the objective has always been responsible regulation that protects the public whilst expanding access to safe, transparent, and accountable healthcare options.

Connecticut has already demonstrated that responsible regulation, consumer protection, and evidence-based healthcare policy can coexist. The state should lead the next chapter of hemp policy by encouraging federal lawmakers to strengthen national standards while preserving successful state regulatory systems, particularly the one Connecticut has already demonstrated can work.

John R. Gordon is director of Healthcare Policy and External Affairs for the American Alternative Care Policy Network and a volunteer first responder. He lives in Greenwich, Connecticut.

Originally published: Hartford Courant, August 19, 2026. Read the original commentary at the Hartford Courant.